dc.contributor.author | Doğu, Mehmet Hilmi | |
dc.contributor.author | Tekgündüz, Ali İrfan Emre | |
dc.contributor.author | Deveci, Burak | |
dc.contributor.author | Korkmaz, Gülten | |
dc.contributor.author | Cömert, Melda | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.contributor.author | Yokuş, Osman | |
dc.contributor.author | Serin, İstemi | |
dc.date.accessioned | 2023-05-26T11:02:10Z | |
dc.date.available | 2023-05-26T11:02:10Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Doğu, M. H., Tekgündüz, A. İ. E., Deveci, B., Korkmaz, G., Cömert, M., Sevindik, Ö. G. ... Serin, İ. (2023). Gilteritinib (XOSPATA (R)) in Turkey: Early access program results. Mediterranean Journal of Hematology and Infectious Diseases, 15(1). https://doi.org/10.4084/MJHID.2023.031 | en_US |
dc.identifier.issn | 2035-3006 | |
dc.identifier.uri | https://doi.org/10.4084/MJHID.2023.031 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10979 | |
dc.description.abstract | Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute myeloid leukemia (AML) patients who harbored any FLT3 mutation and showed superior efficacy with regard to response and survival. Objectives: This research aimed to investigate the real-life efficacy and safety of gilteritinib in FLT3-positive R/R AML patients who were treated as a part of an early access program held in Turkey in April 2020 (NCT03409081). Results: The research included 17 R/R AML patients who had received gilteritinib from seven centers. The overall response rate was 100%. The most common adverse events were anemia and hypokalemia (7 patients, 41.2%). Grade 4 thrombocytopenia was observed in one patient only (5.9%), leading to permanent treatment discontinuation. Patients with peripheral edema had a 10.47 (95% CI: 1.64-66.82) times higher risk of death than those without peripheral edema (p<0.05). Conclusion: This research showed that patients with febrile neutropenia and peripheral edema were at a high risk of death when compared to patients without febrile neutropenia and peripheral edema. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Mattioli 1885 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Gilteritinib | en_US |
dc.subject | Acute Myeloid Leukemia (AML) | en_US |
dc.subject | Early Access | en_US |
dc.subject | Real-Life Data | en_US |
dc.subject | Response | en_US |
dc.subject | Prognosis | en_US |
dc.title | Gilteritinib (XOSPATA (R)) in Turkey: Early access program results | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Mediterranean Journal of Hematology and Infectious Diseases | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 15 | en_US |
dc.identifier.issue | 1 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.4084/MJHID.2023.031 | en_US |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.wos | 000983087400001 | en_US |
dc.identifier.scopus | 2-s2.0-85160615870 | en_US |
dc.identifier.pmid | 37180209 | en_US |
dc.identifier.scopusquality | Q2 | en_US |